Liraglutide (NN2211) is a long-acting glucagon-like peptide-1 receptor agonist, binding to the same receptors as does the endogenous metabolic hormone GLP-1 that stimulates insulin secretion.
Marketed under the brand name Victoza, liraglutide is an injectable drug developed for the treatment of type 2 diabetes.
|